CoChat

Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials

Open access
Kong, Wenqiang, Deng, Huiyuan, Wan, Jie, Zhou, Yilu, Zhou, Yan, Song, Bihui, Wang, Xiuling · 2020 · Frontiers in Pharmacology
Cited by 44

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: Generalized anxiety disorder (GAD) is one of the most common psychiatric disorders associated with substantial dysfunction and socioeconomic burden. Pharmacotherapy is the first choice for GAD. Remission [Hamilton Anxiety Scale (HAM-A) score ≤7] is regarded as a crucial treatment goal for patients with GAD. There is no up-to-date evidence to compare remission rate and tolerability of all available drugs by using network meta-analysis. Therefore, the goal of our study is to update evidence and determine the best advantageous drugs for GAD in remission rate and tolerability profiles. Method: We performed a systematic review and network meta-analysis of double-blind randomized controlled trials (RCTs). We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, wanfang data, China Biology Medicine and ClinicalTrials.gov from their inception to March 2020 to identify eligible double-blind, RCTs reporting the outcome of remission in adult patients who received any pharmacological treatment for GAD. Two reviewers independently assessed quality of included studies utilizing the Cochrane Collaboration’s risk of bias tool as described in Cochrane Collaboration Handbook and extracted data from all manuscripts. Our outcomes were remission rate (proportion of participants with a final score of seven or less on HAM-A) and tolerability (treatments discontinuations due to adverse events). We calculated summary odds ratios (ORs) and 95% confidence intervals (CIs) of each outcome via pairwise and network meta-analysis with random effects. Results: Overall, 30 studies were included, comprising 32 double-blind RCTs, involving 13,338 participants diagnosed as GAD by DSM-IV criteria. Twenty-eight trials were rated as moderate risk of bias, four trials as low. For remission rate, agomelatine (OR 2.70, 95% CI 1.74–4.19), duloxetine (OR 1.88, 95% CI 1.47–2.40), escitalopram (OR 2.03, 95% CI 1.48–2.78), paroxetine (OR 1.74, 95% CI 1.25–2.42), quetiapine (OR 1.88, 95% CI 1.39–2.55), and venlafaxine (OR 2.28, 95% CI 1.69–3.07) were superior to placebo. For tolerability, sertraline, agomelatine, vortioxetine, and pregabalin were found to be comparable to placebo. However, the others were worse than placebo in terms of tolerability, with ORs ranging between 1.86 (95% CI 1.25–2.75) for tiagabine and 5.98 (95% CI 2.41–14.87) for lorazepam. In head-to-head comparisons, agomelatine, duloxetine, escitalopram, quetiapine, and venlafaxine were more efficacious than tiagabine in terms of remission rate, ORs from 1.66 (95% CI 1.04–2.65) for duloxetine to 2.38 (95% CI 1.32–4.31) for agomelatine. We also found that agomelatine (OR 2.08, 95% CI 1.15–3.75) and venlafaxine (OR 1.76, 95% CI 1.08–2.86) were superior to vortioxetine. Lorazepam and quetiapine were poorly tolerated when compared with other drugs. Conclusions: Of these interventions, only agomelatine manifested better remission with relatively good tolerability but these results were limited by small sample sizes. Duloxetine, escitalopram, venlafaxine, paroxetine, and quetiapine showed better remission but were poorly tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.580858

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 46

  1. Alaka, 2014, Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial, Int. J. Geriatr. Psychiatr., 29, 978, 10.1002/gps.4088 · DOI · Paper page
  2. Allgulander, 2004, Efficacy of sertraline in a 12-week trial for generalized anxiety disorder, Am. J. Psychiatr., 161, 1642, 10.1176/appi.ajp.161.9.1642 · DOI · Paper page
  3. Baldwin, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ, 342, d1199, 10.1136/bmj.d1199 · DOI · Paper page
  4. Baldwin, 2011, Evidence-based pharmacological treatment of generalized anxiety disorder, Int. J. Neuropsychopharmacol., 14, 697, 10.1017/s1461145710001434 · DOI · Paper page
  5. Ball, 2015, Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorder, Int. Psychogeriatr., 27, 1533, 10.1017/s1041610215000381 · DOI
  6. Bidzan, 2012, Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial, Eur. Neuropsychopharmacol, 22, 847, 10.1016/j.euroneuro.2012.07.012 · DOI
  7. Bose, 2008, Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder, Depress. Anxiety, 2, 854, 10.1002/da.20355 · DOI · Paper page
  8. Boyer, 2004, Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release, Eur. Psychiatr., 19, 272, 10.1016/j.eurpsy.2004.05.010 · DOI
  9. Coric, 2010, Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder, Depress. Anxiety, 27, 417, 10.1002/da.20695 · DOI · Paper page
  10. Davidson, 2004, Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study, Depress. Anxiety, 19, 234, 10.1002/da.10146 · DOI · Paper page
  11. Doyle, 2003, Establishment of remission criteria for anxiety disorders, J. Clin. Psychiatr., 40
  12. Feltner, 2003, A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder, J. Clin. Psychopharmacol., 23, 240, 10.1097/01.jcp.0000084032.22282.ff · DOI · Paper page
  13. Freiesleben, 2015, A systematic review of agomelatine-induced liver injury, J. Mol. Psychiatry, 3, 4, 10.1186/s40303-015-0011-7 · DOI · Paper page
  14. Guardiola-Lemaitre, 2014, Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties, Br. J. Pharmacol., 171, 3604, 10.1111/bph.12720 · DOI · Paper page
  15. Hartford, 2007, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial, Int. Clin. Psychopharmacol., 22, 167, 10.1097/yic.0b013e32807fb1b2 · DOI · Paper page
  16. He, 2019, Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis, J. Psychiatr. Res., 118, 21, 10.1016/j.jpsychires.2019.08.009 · DOI · Paper page
  17. Higgins, 2011, The Cochrane collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
  18. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  19. Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of Health Care interventions: checklist and explanations, Ann. Intern. Med., 162, 777, 10.7326/m14-2385 · DOI · Paper page
  20. Kasper, 2014, Lavender oil preparation silexan is effective in generalized anxiety disorder–a randomized, double-blind comparison to placebo and paroxetine, Int. J. Neuropsychopharmacol., 17, 859, 10.1017/s1461145714000017 · DOI · Paper page
  21. Khan, 2011, A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder, J. Clin. Psychopharmacol., 31, 418, 10.1097/jcp.0b013e318224864d · DOI · Paper page
  22. Koponen, 2007, Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary Care physicians, Prim. Care Companion J. Clin. Psychiatry, 9, 100, 10.4088/pcc.v09n0203 · DOI · Paper page
  23. Laporte, 2017, Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies, Pharmacol. Res., 118, 19, 10.1016/j.phrs.2016.08.017 · DOI · Paper page
  24. Lenox-Smith, 2003, A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary Care, Br. J. Gen. Pract., 53, 772
  25. Li, 2017, Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose Co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials, Diabetes Obes. Metabol., 19, 348, 10.1111/dom.12825 · DOI · Paper page
  26. Mahableshwarkar, 2014, A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder, Int. J. Clin. Pract., 68, 49, 10.1111/ijcp.12328 · DOI · Paper page
  27. Mandos, 2009, Achieving remission in generalized anxiety disorder. What are the treatment options?, Psychiatr. Times, 26, 38
  28. Maneeton, 2016, Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials, Drug Des. Devel. Ther., 10, 259, 10.2147/dddt.s89485 · DOI · Paper page
  29. Merideth, 2012, Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study, Int. Clin. Psychopharmacol., 27, 40, 10.1097/yic.0b013e32834d9f49 · DOI · Paper page
  30. Mezhebovsky, 2013, Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder, Int. J. Geriatr. Psychiatr., 28, 615, 10.1002/gps.3867 · DOI · Paper page
  31. Millan, 2003, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways, J. Pharmacol. Exp. Ther., 306, 954, 10.1124/jpet.103.051797 · DOI · Paper page
  32. Montgomery, 2008, Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder, Br. J. Psychiatry, 193, 389, 10.1192/bjp.bp.107.037788 · DOI · Paper page
  33. Nicolini, 2009, Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial, Psychol. Med., 39, 267, 10.1017/s0033291708003401 · DOI · Paper page
  34. Nimatoudis, 2004, Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study, Int. Clin. Psychopharmacol., 19, 331, 10.1097/00004850-200411000-00003 · DOI · Paper page
  35. Pollack, Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint, J. Psychiatr. Res., 42, 1176, 10.1016/j.jpsychires.2008.02.002 · DOI
  36. Pollack, Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies, J. Clin. Psychopharmacol., 28, 308, 10.1097/jcp.0b013e318172b45f · DOI · Paper page
  37. Pollack, 2001, Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial, J. Clin. Psychiatr., 62, 350, 10.4088/jcp.v62n0508 · DOI · Paper page
  38. Qin, 2019, Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes, BMJ Open, 9, e033161, 10.1136/bmjopen-2019-033161 · DOI
  39. Rickels, 2003, Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study, Am. J. Psychiatry, 160, 749, 10.1176/appi.ajp.160.4.749 · DOI · Paper page
  40. Rothschild, 2012, Vortioxetine (Lu AA21004) 5 Mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, Eur. Neuropsychopharmacol, 22, 858, 10.1016/j.euroneuro.2012.07.011 · DOI
  41. Rynn, 2008, Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial, Depress. Anxiety, 25, 182, 10.1002/da.20271 · DOI · Paper page
  42. Stack, 2013, Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example, Ann. Intern. Med., 159, 285, 10.7326/0003-4819-159-4-201308200-00009 · DOI
  43. Stein, 2008, Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychopharmacol., 28, 561, 10.1097/jcp.0b013e318184ff5b · DOI · Paper page
  44. Stein, 2011, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies, Hum. Psychopharmacol. Clin. Exp., 26, 614, 10.1002/hup.1256 · DOI
  45. Stein, 2017, Efficacy and safety of agomelatine (10 or 25 Mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study, Eur. Neuropsychopharmacol, 27, 526, 10.1016/j.euroneuro.2017.02.007 · DOI · Paper page
  46. Wu, 2011, Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China, Chin. Med. J., 124, 3260, 10.3760/cma.j.issn.0366-6999.2011.20.010 · doi:10.3760/cma.j.issn.0366-6999.2011.20.010

Cited by

Metadata

Authors
Kong, W., Deng, H., Wan, J., Zhou, Y., Zhou, Y., Song, B., & Wang, X.
Venue
Frontiers in Pharmacology
Published
2020-11-11
Volume
11
Pages
580858-580858
ISSN
1663-9812 (ISSN-L)
OpenAlex
W3103418528
Cited by
44
References
15
FWCI
0.80
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.